- Current report filing (8-K)
April 16 2009 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 16, 2009
AMYLIN PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-19700
|
|
33-0266089
|
(State
or Other Jurisdiction of
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
Incorporation)
|
|
|
|
|
9360 Towne Centre Drive
San Diego, California 92121
(Address
of principal executive offices and zip code)
Registrants
telephone number, including area code:
(858) 552-2200
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
o
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
x
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item 2.02. Results of
Operations and Financial Condition.
On April 16, 2009, Amylin Pharmaceuticals, Inc. issued a
press release announcing its financial results for the quarter ended March 31,
2009. A copy of this press release is attached as Exhibit 99.1 and
is incorporated herein by reference.
On April 16, 2009, Amylin will webcast a properly noticed
quarterly update conference call for the quarter ended March 31,
2009. A copy of the presentation to be
used in connection with this conference call is attached as Exhibit 99.2
and is incorporated herein by reference.
Item 8.01. Financial
Statements and Exhibits.
The information provided in Item 2.02 to this Current Report on Form 8-K
is herein incorporated by reference.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
release issued by Amylin on April 16, 2009
|
|
|
|
99.2
|
|
Quarterly
update conference call presentation for the quarter ended March 31, 2009
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMYLIN PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Dated:
April 16, 2009
|
|
By:
|
/s/
Lloyd A. Rowland
|
|
|
|
Lloyd
A. Rowland
|
|
|
|
Vice President, Governance and Compliance,
and Corporate Secretary
|
3
EXHIBIT INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
release issued by Amylin on April 16, 2009.
|
|
|
|
99.2
|
|
Quarterly
update conference call presentation for the quarter ended March 31,
2009.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024